Silence Therapeutics (SLN)

• Market cap: $148M
• 1 day: 8.28%
• 5 days: 42.08%
• 1 month: -19.49%
• 3 months: -38.67%
• 6 months: -83.03%
• Year to date: -56.33%
• 1 year: -85.44%
• 5 years: -83.90%
• 10 years: -83.90%
• Sector: Healthcare
• Industry: Biotechnology

About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Employees: 116

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

77% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 13

2.43% less ownership

Funds ownership: 20.14% [Q3] → 17.71% (-2.43%) [Q4]

6% less funds holding

Funds holding: 69 [Q3] → 65 (-4) [Q4]

20% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 20

40% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]

66% less capital invested

Capital invested by funds: $493M [Q3] → $168M (-$325M) [Q4]

91% less call options, than puts

Call options by funds: $3K | Put options by funds: $34K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 27% upside
• Avg. target: $37 1,086% upside
• High target: $75 2,289% upside

4 analyst ratings

• positive: 3 75%
• neutral: 0 0%
• negative: 1 25%

HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target	2,289% upside $75	Buy Reiterated	7 Mar 2025
Morgan Stanley Michael Ulz 20% 1-year accuracy 4 / 20 met price target	1,333% upside $45	Overweight Maintained	5 Mar 2025
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target	696% upside $25	Outperform Maintained	4 Mar 2025
Goldman Sachs Richard Law 50% 1-year accuracy 4 / 8 met price target	27% upside $4	Sell Maintained	4 Mar 2025